Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Plus Endocrine Therapy in ER+/HER2- Breast Cancer With CD8+ T-cell Infiltration (Phase II)
2016-000764-42Phase 2Completed
- Sponsor
- Unicancer
- Start
- Nov 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of durvalumab in breast cancer, sponsored by Unicancer. Primary endpoint: Pathological complete response rate. Started Nov 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-000764-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000764-42.